Plasma cells
B cells are well known for their ability to produce antibodies that are vital to neutralize foreign entities or infected cells. Antibody secreting cells (ASCs), which include plasmablasts and plasma cells, lack the CD20 B cell marker and in humans express a combination of CD27, CD38 and CD138. Plasmablasts act early during adaptive immune responses, produce low-affinity immunoglobulins and have a short life. Plasma cells are more differentiated and comprise a short-lived and a long-lived subset. Short-lived plasma cells are similar to plasmablasts in their lifespan and antibody secretion rate and while plasmablasts express all immunoglobulin (Ig) isotypes, plasma cells have a preference for IgM and IgG. Long-lived plasma cells have the longest lifespan and the highest rate of antibody secretion with immunoglobulin (Ig) isotypes being IgG > IgA > IgM.1
Effector B cells
Effector B cells or B-eff play a supportive role to immune responses through antigen presentation and secrete an array of cytokines (e.g., IL-2, IL-6, GM-CSF, IL-12, IL-17, IFN-γ, TNF-α) to induce activation of macrophages (e.g., interferon-gamma), T cell differentiation (IL-6 for Th17) and plasma cell differentiation for antibody production.2 Effector B cells also contribute to unregulated immune responses by supporting plasma cell differentiation for autoantibody production in autoimmune diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS). In MS, CD138+ B cells have been shown to accumulate in the cerebrospinal fluid (CSF) and contribute in maintaining chronic inflammation in the CNS through inflammatory cytokine secretion and resident microglia activation.3
Regulatory B cells
As B cells secrete cytokines to regulate the functions of immune cells, they also receive environmental signals from immune counterparts that regulate their functions. In autoimmunity, a balance between effector B cells and regulatory B cells (B-reg) can be induced by macrophage and dendritic cell-derived BAFF. In SLE, excess BAFF promotes autoantibody production by plasma cells while inhibiting activation of IL-10 producing B-regs. Most of these IL-10 secreting regulatory B cells can be identified by CD9 (88%) and tumor necrosis factor receptor 2 (TNFR2) expression.2, 4